Peak Bio, a South Korean clinical-stage biopharmaceutical company, has agreed to go public on Nasdaq through a merger with blank cheque company Ignyte Acquisition Corp in a deal that values the combined business at $278 million.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
